Pure Global

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects - Trial NCT06350812

Access comprehensive clinical trial information for NCT06350812 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by PegBio Co., Ltd. and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06350812
Phase 1/2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06350812
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects
A Single-center, Randomized, Double-blind, Placebo-controlled, Multiple Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects

Study Focus

Obesity

PB-119

Interventional

drug

Sponsor & Location

PegBio Co., Ltd.

Timeline & Enrollment

Phase 1/2

May 30, 2024

Apr 29, 2025

32 participants

Primary Outcome

Incidence of Treatment-Emergent Adverse Events

Summary

The trial is conducted in a single-center, randomized, double-blind, placebocontrolled,
 dose-increasing design. To evaluate the safety, tolerability, PK characteristics, efficacy
 and immunogenicity of PB-119 injection in Chinese obese subjects.

ICD-10 Classifications

Obesity
Other obesity
Obesity, unspecified
Obesity due to excess calories
Obesity and other hyperalimentation

Data Source

ClinicalTrials.gov

NCT06350812

Non-Device Trial